Enterovirus 71 infection

Enterovirus 71 infection is presented in the source set as an enteroviral infection concept, but the provided snippets do not include a substantive etiologic or case-definition narrative beyond the disease name itself ^[1][2][3]. The available records mainly point to review literature on enterovirus 71 infection, severe enterovirus 71 infection, and enterovirus 71 infection and vaccines, indicating that the topic has been addressed in virology, pediatric, and vaccine-related scholarship ^[1][2][3].

Source-backed clinical description is not yet available in the provided snippets. One cited article title indicates that severe enterovirus 71 infection is a recognized topic in the literature, but the payload does not supply specific symptoms, complications, or course characteristics ^[2]. No further clinical pattern, prognostic feature, or complication profile can be stated from the supplied evidence ^[1][2][3].

The supplied sources do not provide geographic distribution, outbreak size, reservoir information, seasonality, or surveillance burden for enterovirus 71 infection ^[1][2][3]. What can be stated conservatively is that the topic has generated review literature in 2014 and 2017 and a paper specifically focused on severe infection in 2007, suggesting sustained scholarly attention over time ^[1][2][3]. No source-backed epidemiologic detail beyond these publication metadata are available ^[1][2][3].

The provided snippets do not describe routes of transmission, exposure settings, or persistence mechanisms for enterovirus 71 infection ^[1][2][3]. Transmission-related detail is therefore not yet available from the supplied evidence boundary ^[1][2][3].

The supplied snippets do not identify age groups, comorbidities, occupational exposures, or other high-risk populations for enterovirus 71 infection ^[1][2][3]. Any risk-group assignment would be speculative on the basis of the current evidence boundary, so source-backed detail is not yet available ^[1][2][3].

A vaccine-focused publication title is present in the source set, which indicates that prevention through vaccination has been a subject of published review ^[3]. However, the snippets do not provide vaccine composition, schedule, effectiveness, or any additional prevention measures, so those details are not yet available from the supplied sources ^[3].

In surveillance terms, the payload supports only a minimal monitoring concept: enterovirus 71 infection is a named viral entity with associated literature on severe disease and vaccines, but the excerpts do not define notification criteria, laboratory confirmation, or reporting thresholds ^[1][2][3]. This record should therefore be read as a placeholder for a disease concept rather than as a source of operational surveillance specifications ^[1][2][3].

1. 1 Update on enterovirus 71 infection. Current Opinion in Virology. 2014. doi: 10.1016/j.coviro.2014.03.007. DOI: https://doi.org/10.1016/j.coviro.2014.03.007
2. 2 Severe enterovirus 71 infection. Archives of Disease in Childhood. 2007. doi: 10.1136/adc.2007.121525. DOI: https://doi.org/10.1136/adc.2007.121525
3. 3 Enterovirus 71 infection and vaccines. Clinical and Experimental Vaccine Research. 2017. doi: 10.7774/cevr.2017.6.1.4. DOI: https://doi.org/10.7774/cevr.2017.6.1.4
4. 4 Pironi L et al. ESPEN practical guideline: Home parenteral nutrition. Clin Nutr. 2023 Mar. PMID: 36796121. doi: 10.1016/j.clnu.2022.12.003. PubMed: https://pubmed.ncbi.nlm.nih.gov/36796121/
5. 5 Pironi L et al. ESPEN guideline on home parenteral nutrition. Clin Nutr. 2020 Jun. PMID: 32359933. doi: 10.1016/j.clnu.2020.03.005. PubMed: https://pubmed.ncbi.nlm.nih.gov/32359933/
6. 6 Bischoff SC et al. ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. Clin Nutr. 2023 Mar. PMID: 36739756. doi: 10.1016/j.clnu.2022.12.004. PubMed: https://pubmed.ncbi.nlm.nih.gov/36739756/

ICD-10

B34.1

ICD-11

1F01

Total cases

563

Peak month

2010-06

Coverage

1 reporting countries · 2009-03-01 → 2026-05-01